The European Medicines Agency Review of Pomalidomide in Combination With Low-Dose Dexamethasone for the Treatment of Adult Patients With Multiple Myeloma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

On August 5, 2013, a marketing authorization valid throughout the European Union (EU) was issued for pomalidomide in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior treatment regimens, includin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Hanaizi, Zahra, Flores, Beatriz, Hemmings, Robert, Camarero, Jorge, Sancho-Lopez, Arantxa, Salmonson, Tomas, Gisselbrecht, Christian, Laane, Edward, Pignatti, Francesco
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2015
Témata:
Regulatory Issues: EMA
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4350811/
https://ncbi.nlm.nih.gov/pubmed/25673103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0073
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky